PCI Biotech announces preliminary outcome of meetings with EMA and FDA for development of fimaporfin in inoperable cholangiocarcinoma NewsRonny SkuggedalDecember 20, 2017
PCI Biotech receives US Orphan Drug Designation for fimaporfin in the treatment of bile duct cancer (cholangiocarcinoma) NewsRonny SkuggedalOctober 5, 2017
Initial clinical results from Phase I indicate that vaccination with fimaVacc enhances cellular immune responses NewsRonny SkuggedalSeptember 12, 2017
Exercise of employee share options, mandatory notification of trade and resolution to increase the share capital NewsRonny SkuggedalSeptember 6, 2017
PCI Biotech appoints Dr Hans Olivecrona as Chief Medical Officer NewsRonny SkuggedalAugust 23, 2017
Extension of preclinical research collaboration agreement with a top-10 large pharma company NewsRonny SkuggedalJuly 10, 2017
PCI Biotech and RXi Pharmaceuticals Extend Research Collaboration to the Field of Immuno-oncology NewsRonny SkuggedalMay 22, 2017
